Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
3. C.R. Bard scores reimbursement win for Lutonix
C.R. Bard said that the U.S. Centers for Medicare and Medicaid Services (CMS) has approved a pass-through payment for the Lutonix drug-coated balloon, which won FDA approval earlier this month.
The Lutonix device is the 1st DEB to hit the U.S. market. It’s designed to dilate obstructions in the superficial femoral or popliteal arteries and leave behind a therapeutic dose of paclitaxel, a drug that’s also used to coat drug-eluting stents. FDA granted pre-market approval for the drug-eluting balloon for treating peripheral artery disease earlier this month. Read more
2. 3M to buy Ivera Medical
3M Cos. announced it has entered into an agreement to buy disinfectant-products maker Ivera.
Ivera’s lead product, the Curos I.V. port-connector cap, is used to help prevent catheter-related blood-stream infections, or CRBSIs. 3M said the product will complement its Tegaderm line of antimicrobial I.V. securement dressings. Read more
1. Renal Denervation: Medtronic taking another shot at drug-resistant hypertension
More than a year after Medtronic said its Symplicity renal denervation device failed to meet its efficacy endpoint in a U.S. pivotal trial, the global device giant is taking another shot.
Medtronic Chief Financial Officer Gary Ellis revealed during the company’s recent earnings call that the Fridley, Minn.-based med tech giant plans to submit a U.S. investigational device exemption application for its global renal denervation clinical program sometime soon. Read more
